Polygenic Score (PGS) ID: PGS003487

Predicted Trait
Reported Trait General atopic disease (IL-4 related variants)
Mapped Trait(s) allergic disease (MONDO_0005271)
Released in PGS Catalog: April 12, 2023
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name PRS_IL4
Development Method
Name Genome-wide significant SNPs
Parameters r2<0.2, SNPS implicated in the IL-4/13 pathway
Variants
Original Genome Build hg19
Number of Variants 25
Effect Weight Type beta
PGS Source
PGS Catalog Publication (PGP) ID PGP000451
Citation (link to publication) Al-Janabi A et al. J Invest Dermatol (2023)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 100%
1,225,820 individuals (100%)
PGS Evaluation
European: 100%
1 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
JSONXMLCSVTXTMS-Excel
Loading, please wait
Study Identifiers
Sample Numbers
Sample Ancestry
Cohort(s)
doi.org/10.1101/2022.10.05.22279072
[
  • 60,653 cases
  • , 804,329 controls
]
EuropeanNR
GWAS Catalog: GCST005038
Europe PMC: 29083406
360,838 individualsEuropeanNR
Showing 1 to 2 of 2 rows

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

JSONXMLCSVTXTMS-Excel
Loading, please wait
PGS Performance
Metric ID (PPM)
PGS Sample Set ID
(PSS)
Performance Source
Trait
PGS Effect Sizes
(per SD change)
Classification Metrics
Other Metrics
Covariates Included in the Model
PGS Performance:
Other Relevant Information
PPM017415PSS010186|
European Ancestry|
3,212 individuals
PGP000451 |
Al-Janabi A et al. J Invest Dermatol (2023)
Reported Trait: Paradoxical eczema in biologic-treated psoriasisOR: 2.08 [0.7, 6.06]——PCs 1-2—
Showing 1 to 1 of 1 rows

Evaluated Samples

JSONXMLCSVTXTMS-Excel
Loading, please wait
PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods
Participant Follow-up Time
Sample Numbers
Age of Study Participants
Sample Ancestry
Additional Ancestry Description
Cohort(s)
Additional Sample/Cohort Information
PSS010186Plaque psoriasis patients with at least one exposure to biologic therapy. Cases developed one or mor... e paradoxical eczema adverse events during treatment with one of the following biologics: TNF-alpha inhibitors (adalimumab; etanercept; certolizumab; infliximab), IL-17 inhibitors (brodalumab; secukinumab; ixekizumab), IL-12/23 inhibitors (ustekinumab) and IL-23p19 inhibitors (guselkumab; risankizumab; tildrakizumab). Controls has no recorded eczema events during biologic therapy. Participants may have been exposed to more than one biologic.Show more—
[
  • 88 cases
  • , 3,124 controls
]
—European—BSTOP—
Showing 1 to 1 of 1 rows